| Lawitz, Eric |
NCT06165341: Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis) |
|
|
| Recruiting | 3 | 50 | Europe, Canada, US | Fazirsiran Injection, TAK-999, ARO-AAT, ADS-001, Placebo | Takeda | Alpha1-Antitrypsin Deficiency | 08/28 | 08/28 | | |
NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( ) |
|
|
| Recruiting | 3 | 1000 | Europe, Canada, US, RoW | IVA337, Lanifibranor, Placebo | Inventiva Pharma | NASH - Nonalcoholic Steatohepatitis | 09/25 | 09/26 | | |
NCT05677971: Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein |
|
|
| Recruiting | 3 | 160 | Europe, Canada, US, RoW | Fazirsiran Injection, TAK-999, ARO-AAT, ADS-001, Placebo, Sodium chloride | Takeda, Takeda Development Center Americas, Inc. | Alpha1-Antitrypsin Deficiency | 03/27 | 03/29 | | |
| Terminated | 2b | 98 | Europe, Canada, US, RoW | EDP-305 1.5 mg, EDP-305, EDP-305 2 mg, Placebo | Enanta Pharmaceuticals, Inc, Enanta Pharmaceuticals, Inc. | Non-Alcoholic Steatohepatitis | 10/21 | 11/21 | | |
| Active, not recruiting | 2b | 357 | Europe, Canada, US, RoW | belapectin, GR-MD-02, galactoarabino rhamnogalacturonate, Placebo | Galectin Therapeutics Inc., Galectin Therapeutics Inc | Prevention of Esophageal Varices, NASH - Nonalcoholic Steatohepatitis, Cirrhosis | 12/24 | 12/24 | | |
NCT05591079: A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CS0159 in Subjects With NASH |
|
|
| Completed | 2 | 99 | US | CS0159 (Linafexor), placebo | Cascade Pharmaceuticals, Inc, Laboratory Corporation of America | Nonalcoholic Steatohepatitis (NASH) | 11/23 | 11/23 | | |
LEGEND, NCT05232071: Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus |
|
|
| Completed | 2 | 42 | Europe, US | IVA337, Lanifibranor, Placebo, Empagliflozin, Jardiance | Inventiva Pharma | NASH - Nonalcoholic Steatohepatitis, Diabetes Mellitus, Type 2 | 03/24 | 06/24 | | |
| Active, not recruiting | 2 | 60 | US | Bezafibrate 100 mg, Bezafibrate 200 mg, Obeticholic Acid 5 mg, Obeticholic Acid placebo, Bezafibrate Placebo | Intercept Pharmaceuticals, Intercept Pharmaceuticals, Inc. | Primary Biliary Cholangitis | 11/24 | 02/25 | | |
| Active, not recruiting | 2 | 68 | Europe, US, RoW | Anti-human CCL24 monoclonal antibody (CM-101), Placebo | ChemomAb Ltd., ChemomAb Ltd | Primary Sclerosing Cholangitis | 09/24 | 09/25 | | |
NCT05979779: Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis |
|
|
| Active, not recruiting | 2 | 219 | US | HU6, Placebo | Rivus Pharmaceuticals, Inc. | Non-Alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, Fatty Liver | 02/25 | 04/25 | | |
STARLIGHT, NCT06613698: A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 65 Years With Alcohol-related Liver Disease |
|
|
| Not yet recruiting | 2 | 393 | Europe, Canada, Japan, US, RoW | GSK4532990, Placebo | GlaxoSmithKline | Liver Diseases, Alcoholic | 12/26 | 03/27 | | |
NCT04505436: Study to Evaluate Efficacy, Safety and Tolerability of HM15211 in Subjects |
|
|
| Recruiting | 2 | 240 | US, RoW | HM15211, Placebo of HM15211 | Hanmi Pharmaceutical Company Limited | NASH - Nonalcoholic Steatohepatitis | 05/26 | 11/26 | | |
| Recruiting | 2 | 48 | US | GSK4532990 | GlaxoSmithKline | Non-alcoholic Fatty Liver Disease | 06/25 | 06/25 | | |
| Active, not recruiting | 2 | 271 | Europe, Canada, Japan, US, RoW | GSK4532990, Placebo | GlaxoSmithKline, GlaxoSmithKline Research & Development Limited | Nonalcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver Disease | 12/25 | 03/26 | | |
NCT05104853: Study to Evaluate the Safety, Tolerability, PDs, and Efficacy of CNP-104 in Subjects with Primary Biliary Cholangitis |
|
|
| Active, not recruiting | 1/2 | 42 | US | CNP-104, Placebo | COUR Pharmaceutical Development Company, Inc. | Primary Biliary Cholangitis | 01/26 | 01/26 | | |
NCT05961397: Phase 1 PK Study to Evaluate the PK of CIN-107 in Subjects With Hepatic Impairment |
|
|
| Completed | 1 | 20 | US | baxdrostat, CIN-107 | AstraZeneca | Hypertension | 04/22 | 04/22 | | |
NCT05599932: Pharmacokinetics and Safety Study of Siremadlin (HDM201) in Participants With Mild, Moderate and Severe Hepatic Impairment |
|
|
| Completed | 1 | 38 | US | Siremadlin, HDM201 | Novartis Pharmaceuticals | Hepatic Impairment | 09/23 | 09/23 | | |
NCT05440344: A Study of Imlunestrant (LY3484356) in Female Participants With Impaired Liver Function |
|
|
| Completed | 1 | 28 | US | Imlunestrant, LY3484356 | Eli Lilly and Company | Hepatic Insufficiency, Healthy | 02/24 | 02/24 | | |
NCT05490888: Single and Multiple Dose Escalation of PHIN-214 in Child-Pugh A and B Liver Cirrhotics |
|
|
| Recruiting | 1 | 62 | US | PHIN-214 Subcutaneous injection, Terlipressin derivative | PharmaIN | Cirrhosis, Liver, Liver Fibrosis, Ascites Hepatic | 10/25 | 12/25 | | |
NCT06084104: DZD9008 PK Study in Hepatic Impairment Subjects |
|
|
| Completed | 1 | 17 | US | DZD9008 | Dizal Pharmaceuticals, PPD Development, L.P. | Hepatic Impairment | 06/24 | 10/24 | | |
NCT05864391: A Study to Investigate Safety, Tolerability, and Pharmacokinetics of AZD7503 in Participants With Suspected NASH. |
|
|
| Terminated | 1 | 40 | US | AZD7503 | AstraZeneca | Steatohepatitis | 03/24 | 03/24 | | |
NCT04469920: Hepatic Impairment, Cholestatic Liver Disease, & NASH with Advanced Fibrosis & Normal Hepatic Function |
|
|
| Completed | 1 | 98 | US | Saroglitazar Magnesium 2 mg, Not any, Saroglitazar Magnesium 4 mg | Zydus Therapeutics Inc. | Hepatic Impairment | 03/22 | 03/22 | | |
NCT04446507: A Pharmacokinetic Study of Saroglitazar Magnesium in Subjects with Severe Renal Impairment and Normal Renal Function |
|
|
| Completed | 1 | 32 | US | Saroglitazar magnesium, not any | Zydus Therapeutics Inc. | Renal Impairment | 05/24 | 05/24 | | |
NCT05329623: A Phase 1 Study to Evaluate the Pharmacokinetics of JDQ443 in Participants With Hepatic Impairment Compared to Matched Healthy Control Participants. |
|
|
| Terminated | 1 | 33 | US | JDQ443 | Novartis Pharmaceuticals | Small Cell Lung Carcinoma | 04/24 | 04/24 | | |
NCT06388616: Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Balcinrenone |
|
|
| Completed | 1 | 30 | US | Balcinrenone, AZD9977 | AstraZeneca | Hepatic Impairment | 09/24 | 09/24 | | |
NCT05882032: A Study of LY3502970 in Participants With Impaired and Normal Liver Function |
|
|
| Completed | 1 | 29 | US | LY3502970 | Eli Lilly and Company | Healthy, Hepatic Insufficiency | 11/24 | 11/24 | | |
NCT05916560: A Study of LY3437943 in Participants With Impaired and Normal Liver Function |
|
|
| Recruiting | 1 | 37 | US | LY3437943 | Eli Lilly and Company | Healthy, Hepatic Insufficiency | 03/25 | 03/25 | | |
NCT05976321: A Study of TAK-279 in Adults With or Without Liver Damage |
|
|
| Completed | 1 | 27 | US | TAK-279 | Takeda | Hepatic Impairment, Healthy Volunteers | 04/24 | 04/24 | | |
NCT06719128: A Study of Olomorasib (LY3537982) in Participants With Hepatic Impairment and Healthy Participants |
|
|
| Not yet recruiting | 1 | 48 | US | Olomorasib, LY3537982 | Eli Lilly and Company | Hepatic Insufficiency, Healthy | 08/25 | 08/25 | | |
| Active, not recruiting | N/A | 1900 | US | Multi-analyte blood Test | Helio Genomics | Liver Cirrhosis | 02/23 | 06/24 | | |
| Landaverde, Carmen |
| Active, not recruiting | 2b | 357 | Europe, Canada, US, RoW | belapectin, GR-MD-02, galactoarabino rhamnogalacturonate, Placebo | Galectin Therapeutics Inc., Galectin Therapeutics Inc | Prevention of Esophageal Varices, NASH - Nonalcoholic Steatohepatitis, Cirrhosis | 12/24 | 12/24 | | |
NCT05591079: A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CS0159 in Subjects With NASH |
|
|
| Completed | 2 | 99 | US | CS0159 (Linafexor), placebo | Cascade Pharmaceuticals, Inc, Laboratory Corporation of America | Nonalcoholic Steatohepatitis (NASH) | 11/23 | 11/23 | | |
NCT04505436: Study to Evaluate Efficacy, Safety and Tolerability of HM15211 in Subjects |
|
|
| Recruiting | 2 | 240 | US, RoW | HM15211, Placebo of HM15211 | Hanmi Pharmaceutical Company Limited | NASH - Nonalcoholic Steatohepatitis | 05/26 | 11/26 | | |
| Garza, Cecilio De La |
| No trials found |
